<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472823</url>
  </required_header>
  <id_info>
    <org_study_id>AG0081</org_study_id>
    <secondary_id>1R01AG028168-01</secondary_id>
    <nct_id>NCT00472823</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in Older Women</brief_title>
  <acronym>VIDOS</acronym>
  <official_title>Determination of RDA for Vitamin D in Caucasian and African American Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of several doses of vitamin D on hormones
      related to bone, calcium absorption, bone density and muscle strength.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of osteoporosis is high in the United States, with about 10 million people
      over the age of 50 already having the disease and another 34 million at risk for developing
      it. Development of low-cost and effective strategies is important for preventing osteoporosis
      and reducing osteoporotic fractures. A simple inexpensive strategy to prevent osteoporosis is
      adequate nutrition with calcium and vitamin D. Serum 25OHD (25-hydroxyvitamin D) is now
      accepted as the objective measure of vitamin D nutrition. There is a growing understanding
      that serum 25OHD concentrations of at least 30-32 ng/ml are needed for optimal bone health at
      which serum parathyroid hormone (PTH) concentrations reach a minimum.

      There are no systematic prospective dose response studies aimed at determining the optimum
      amount of vitamin D intake required to maintain optimum serum 25OHD levels in the population
      which will help in determining the estimated average requirement (EAR) and recommended
      dietary requirement (RDA) for vitamin D. More work to determine the RDA for vitamin D has
      been recommended by the Panel on Calcium and Related Nutrients of the Food and Nutrition
      Board. This study is aimed at filling the information gap by concentrating on the high risk
      group of postmenopausal women. We are testing the theory that increasing serum 25OHD to a
      level greater than 30 ng/ml will reduce serum PTH in the high risk group of vitamin D
      insufficient postmenopausal women with an adequate intake of calcium. We also believe that
      the dose of vitamin D that will achieve this level is approximately 4400IU per day, which is
      well above the suggested adequate intake of 400-600 ID recommended for the elderly.

      In a one year double blind, randomized prospective clinical trial, we will examine the dose
      response effect of supplementation with different doses of vitamin D3 (400, 800, 1600, 2400,
      3200, 4000, 4800IU/day) on the primary outcomes of serum 25OHD and PTH in 160 postmenopausal
      Caucasian and 160 African American women who have inadequate vitamin D levels in winter. We
      expect that the results from this study will add useful and important information about the
      RDA for vitamin D for postmenopausal women who are more susceptible to osteoporosis. The
      results from this study will also help in designing future clinical trials to study the
      effect of vitamin D, for example in preventing fractures, falls, cancer.

      The main objective of the current proposal is to study the effect of increasing doses of
      vitamin D3 in the high risk group of postmenopausal Caucasian and African American women with
      hypovitaminosis D (serum 25OHD &lt;20 ng/ml) in winter in presence of sufficient calcium intake,
      in order to determine the Estimated Average Requirement (EAR) that covers 50% and the
      Recommended Daily allowance (RDA) covers 97.5% of population for vitamin D. We will use a
      serum 25OHD concentration equal &gt;30 ng/ml and normalization of serum PTH as indicators of
      adequacy. We expect that the results from this proposal will add important information
      helpful in designing future larger clinical trials to determine the recommended dietary
      allowance (RDA) for vitamin D in other ethnic groups and designing clinical trials on the
      effect of vitamin D on falls and fractures.

      We hypothesize that increasing serum 25OHD to a level greater than 30 ng/ml with vitamin D
      supplements in 97 percent of the study subjects will reduce serum PTH and bone markers to
      premenopausal range. We postulate that the RDA of vitamin D that will achieve a serum 25OHD
      of â‰¥ 30 ng/ml in 97.5% of women during winter is approximately 4400 IU/d and the EAR dose of
      vitamin D is between 800-1000 IU.

      The specific aims of the proposal are,

        1. To examine the dose response effect of vitamin D3, 400, 800, 1600, 2400, 3200, 4000, and
           4800 IU /d in postmenopausal Caucasian and African American women with hypovitaminosis D
           (serum 25OHD equal &lt;20 ng/ml) in winter plus an adequate calcium intake compared to a
           calcium control group, on serum 25OHD and PTH levels, which constitute our primary
           outcome measures.

        2. To determine the EAR and RDA for postmenopausal women by establishing the dose of
           vitamin D3 that will increase serum 25OHD above 30 ng/ml in 97.5% of study subjects in
           winter and reduce serum PTH to the normal premenopausal range.

        3. To study the dose response effect of vitamin D3 on calcium absorption,
           1,25-dihydroxyvitamin D3 (1,25(OH)2D3) serum calcium, serum bone markers, bone mineral
           density (BMD) and falls (only in elderly) (the secondary outcome measures)

        4. To establish the long term safety of these doses relating to hypercalcemia and
           hypercalciuria

      Progress: Caucasian enrollment completed July 2008; African American enrollment completed May
      2009
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Serum 25-hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) levels</measure>
    <time_frame>Baseline, 6months,12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calcium absorption</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>100mg calcium+ calcium45</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum/urine calcium</measure>
    <time_frame>Baseline and every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone markers</measure>
    <time_frame>Baseline, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>spine,hip,total body,lateral</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>Baseline,6 months,12 months</time_frame>
    <description>leg strength( Cybex),timed up and go,hand grip,chair stand,gait speed,quiet stance,postural stability( biodex),standing balance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Falls</measure>
    <time_frame>Baseline and every 3 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function studies</measure>
    <time_frame>baseline and final test</time_frame>
    <description>FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping</measure>
    <time_frame>one time</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular studies of peripheral leucocytes</measure>
    <time_frame>baseline and final test</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Depression Score</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity Scale form ( PASE)</measure>
    <time_frame>baseline,6 months,12 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sun exposure</measure>
    <time_frame>baseline and every 3 months</time_frame>
    <description>sun exposure form and skin color evaluation by a reflective meter (SmartProbe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic metabolic panel</measure>
    <time_frame>baseline and every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum 1,25 dihydroxyvitamin D</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">273</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>vitamin D3 400 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 400 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D3 800 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 800 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D3 1600 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 1600 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D3 2400 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 2400 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D3 3200 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 3200 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D3 4000 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 4000 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D3 4800 IU daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 4800 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched to vitamin D tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Orally for one year</description>
    <arm_group_label>vitamin D3 400 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 800 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 1600 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 2400 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 3200 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 4000 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 4800 IU daily</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium Citrate (Citracal)</intervention_name>
    <description>Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily</description>
    <arm_group_label>vitamin D3 400 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 800 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 1600 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 2400 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 3200 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 4000 IU daily</arm_group_label>
    <arm_group_label>vitamin D3 4800 IU daily</arm_group_label>
    <other_name>Citracal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 7 years post-menopause

          -  Serum 25OHD level 5 ng/ml to 20 ng/ml

          -  BMI less than or equal to 40 kg/m2

          -  Willing to discontinue multivitamins that contain vitamin D during the study

        Exclusion Criteria:

          -  Cancer (except basal cell carcinoma) or terminal illness

          -  Previous hip fracture

          -  Hemiplegia (paralysis of one side of the body)

          -  Uncontrolled type I diabetes or fasting blood sugar greater than 140 mg in type II

          -  Kidney stones more than twice in a lifetime

          -  Chronic renal failure

          -  Evidence of chronic liver disease, including alcoholism

          -  Physical conditions such as severe osteoarthritis, rheumatoid arthritis, heart failure
             severe enough to prevent reasonable physical activity

          -  Previous treatment with bisphosphonates (more that 3 months), PTH or PTH derivatives,
             (e.g. Teriparatide or Fluoride) in the last 6 months

          -  Previous treatment within the last 6 months with calcitonin or estrogen

          -  Chronic high dose corticosteroid therapy (more than 10 mg per day) for over 6 months
             and not within the last 6 months

          -  Anticonvulsant therapy

          -  High dose thiazide therapy (more than 37.5 mg)

          -  24 hour urine calcium greater than 290 mg on 2 baseline tests

          -  Serum calcium exceeding upper normal limit on 2 baseline tests

          -  Bone Mineral Density T-score less than -3.0 for spine or hip
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>57 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J C Gallagher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gallagher JC, Kinyamu HK, Fowler SE, Dawson-Hughes B, Dalsky GP, Sherman SS. Calciotropic hormones and bone markers in the elderly. J Bone Miner Res. 1998 Mar;13(3):475-82.</citation>
    <PMID>9525348</PMID>
  </reference>
  <reference>
    <citation>Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, Petruschke RA, Chen E, de Papp AE. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005 Jun;90(6):3215-24. Epub 2005 Mar 29.</citation>
    <PMID>15797954</PMID>
  </reference>
  <reference>
    <citation>Aloia JF, Talwar SA, Pollack S, Feuerman M, Yeh JK. Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am J Clin Nutr. 2006 Sep;84(3):602-9.</citation>
    <PMID>16960175</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2007</study_first_submitted>
  <study_first_submitted_qc>May 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2007</study_first_posted>
  <last_update_submitted>March 11, 2016</last_update_submitted>
  <last_update_submitted_qc>March 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cholecalciferol</keyword>
  <keyword>vitamin D deficiency</keyword>
  <keyword>bone density</keyword>
  <keyword>dietary calcium</keyword>
  <keyword>hypercalcemia</keyword>
  <keyword>hypercalciuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

